Mutations induced by some DNA minor groove binding alkylators in AS52 Chinese hamster cells

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 448, Issue 1, 2000, Pages 35-45

  Wu, Xiao C ^a   Marcinkowski, Kasia ^a   Turner, Pamela M ^a   Ferguson, Lynnette R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Chinese hamster AS52 cells; Chlorambucil; Deletion mutation; DNA minor groove binding drugs; Hoechst 33258; Hoechst 33342; Nitrogen mustards

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; CHLORMETHINE; HOE 33342; PIBENZIMOL;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CROSS LINKING; DNA ALKYLATION; DRUG BINDING SITE; DRUG DNA BINDING; DRUG STRUCTURE; GENE DELETION; GENE INDUCTION; GENE MUTATION; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL;

ALKYLATING AGENTS; ANIMALS; BACTERIAL PROTEINS; BENZIMIDAZOLES; BINDING SITES; BISBENZIMIDE; CHLORAMBUCIL; CHO CELLS; CRICETINAE; DNA; ESCHERICHIA COLI PROTEINS; MECHLORETHAMINE; MICRONUCLEUS TESTS; MUTATION; NITROGEN MUSTARD COMPOUNDS; PENTOSYLTRANSFERASES; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTEINS; SEQUENCE DELETION; STRUCTURE-ACTIVITY RELATIONSHIP; THIOGUANINE;

ANIMALIA; BRASSICACEAE; CRICETINAE; CRICETULUS GRISEUS;

EID: 0034646272     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(99)00229-8     Document Type: Article

References (36)

1. Bank B.B. Studies of chlorambucil-DNA adducts. Biochem. Pharmacol. 44:1993;575.
2. Wong S.S., Sturm R.A., Michael J., Zhang X.M., Danoy P.A., McGregor K., Jacobs J.J., Kaushal A., Dong Y., Dunn I.S., Parsons P.G. Transcriptional regulation of differentiation, selective toxicity and ATGCAAAT binding of bisbenzimidazole derivatives in human melanoma cells. Biochem. Pharmacol. 47:1994;827-837.
3. Portugal J., Waring M.J. Assignment of DNA binding sites for 4′,6-diamidine-2-phenylindole and bisbenzimide (Hoechst 33258): a comparative footprinting study. Biochim. Biophys. Acta. 949:1988;158-168.
4. Kraut E.H., Fleming T., Segal M., Neidhart J.A., Behrens B.C., MacDonald M. Phase II study of pibenzimol in pancreatic cancer - a southwest oncology group study. Invest. New Drugs. 9: 1991;95-96.
5. Gravatt G.L., Baguley B.C., Wilson W.R., Denny W.A. DNA-directed alkylating agents: 6. Synthesis and antitumor activity of DNA minor groove-targeted aniline mustard analogues of pibenzimol (Hoechst 33258). J. Med. Chem. 37:1994;4338-4345.
6. Gupta R., Wang H., Huang L., Lown W. Design, synthesis, DNA sequence preferential alkylation and biological evaluation of N-mustard derivatives of Hoechst 33258 analogues. Anti-Cancer Drug Des. 10:1995;25-41.
7. Smail J.B., Fan J.Y., Papa P.V., O'Connor C.J., Denny W.A. Mono- and difunctional nitrogen mustard analogues of the DNA minor groove binder pibenzimol: synthesis, cytotoxicity and interaction with DNA. Anti-Cancer Drug Des. 13:1998;221-242.
8. Brendel M., Ruhland A. Relationships between functionality and genetic toxicology of selected DNA-damaging agents. Mutat. Res. 133:1984;51-85.
9. Yaghi B.M., Turner P.M., Denny W.A., Turner P.R., O'Connor C.J., Ferguson L.R. Comparative mutational spectra of the nitrogen mustard chlorambucil and its half mustard analogue in Chinese hamster AS52 cells. Mutat. Res. 401:1998;153-164.
10. Tindall K.R., Stankowski L.F.J., Machanoff R., Hsie A.W. Detection of deletion mutations in pSV2gpt-transformed cells. Mol. Cell Biol. 4:1984;1411-1415.
11. Tindall K.R., Stankowski L.F.J., Machanoff R., Hsie A.W. Analyses of mutation in pSV2gpt-transformed CHO cells. Mutat. Res. 160:1986;121-131.
12. Sanger F., Nicklen S., Coulson A.R. DNA sequencing with chain-terminator inhibitors. Proc. Natl. Acad. Sci. U.S.A. 74:1977;5463-5467.
13. Fenech M. The cytokinesis-block micronucleus technique: a detailed description of the method and its application to genotoxicity studies in human populations. Mutat. Res. 313:1983;25-44.
14. Tindall K.R., Stankowski L.F.J. Molecular analysis of spontaneous mutations at the gpt locus in Chinese hamster ovary (AS52) cells. Mutat. Res. 220:1989;241.
15. Richardson K.K., Fostel J., Skopek T.R. Nucleotide sequence of the xanthine guanine phosphoribosyl transferase gene of E. coli. Nucleic Acid Res. 11:1983;8809-8816.
16. Hart D.W., Tindall K.R. Identification of repeat sequences within the gpt integration site in AS52 cells. Environ. Mol. Mutagen. 29(Suppl. 28):1997;19.
17. Wilson W.R., Harris N.M., Ferguson L.R. A comparison of the mutagenic and clastogenic activity of amsacrine (NSC 249-992) and other DNA intercalating drugs in cultured V79 Chinese hamster cells. Cancer Res. 44:l984;4420-4431.
18. Ferguson L.R., van Zijl P., Baguley B.C. Mutagenicity profiles of newer amsacrine analogues with activity against solid tumours: comparison of microbial and mammalian systems. Eur. J. Cancer Clin. Oncol. 25:1989;255-261.
19. Ferguson L.R., Hill C.L., Baguley B.C. Genetic toxicology of tricyclic carboxamides, a new class of DNA binding antitumour agent. Eur. J. Cancer Clin. Oncol. 26:1990;709-714.
20. Ferguson L.R., Hill C.L., Morecombe P. Induction of resistance to 6-thioguanine and cytarabine by a range of anticancer drugs in Chinese hamster AA8 cells. Eur. J. Cancer. 28:1992;736-742.
21. Webb S.J., Harrison D.J., Wyllie A.H. Apoptosis: an overview of the process and its relevance in disease. Adv. Pharmacol. 41:1997;1-34.
22. Zhang X.B., Kiechle F.L. Hoechst 33342-induced apoptosis in BC3H-1 myocytes. Ann. Clin. Lab. Sci. 27:1997;260-275.
23. Durand R.E., Olive P.L. Cytotoxicity, mutagenicity and DNA damage by Hoechst 33342. J. Histochem. Cytochem. 30:1982;111-116.
24. Kaldor J.M., Day N.E., Hemminki K. Quantifying the carcinogenicity of antineoplastic drugs. Eur. J. Cancer Clin. Oncol. 24:1988;703-711.
25. Sanderson B.J.S., Shield A.J. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat. Res. 355:1996;41-57.
26. Povirk L.F., Shuker D.E. DNA damage and mutagenesis induced by nitrogen mustards. Mutat. Res. 318:1994;205-226.
27. Loeb L.A. Apurinic sites as mutagenic intermediates. Cell. 40:1985;483-484.
28. Loeb L.A., Preston B.D. Mutagenesis by apurinic/apyrimidinic sites. Annu. Rev. Genet. 20:1986;201-230.
29. Randall S.K., Eritja R., Kaplans B.E., Petruska J., Goodman M.F. Nucleotide insertion kinetics opposite abasic lesions in DNA. J. Biol. Chem. 262:1987;6684-6870.
30. Kunkel T.A. Frameshift mutagenesis by eucaryotic DNA polymerases in vitro. J. Biol. Chem. 261:1986;13581-13587.
31. Kunkel T.A. Misalignment-mediated DNA synthesis errors. Biochemistry. 29:1990;8003-8011.
32. Ferguson L.R., Turner P.M., Hart D.W., Tindall K.R. Amsacrine-induced mutations in AS52 cells. Environ. Mol. Mutagen. 32:1998;47-55.
33. Chen A.Y., Yu C., Bodley A., Peng L.F., Liu L.F. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res. 53:1993;1332-1337.
34. Chen A.Y., Yu C., Gatto B., Liu L.F. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. U.S.A. 90:1993;8131-8135.
35. Beerman T.A., McHugh M.M., Sigmund R., Lown J.W., Rao K.E., Bathini Y. Effects of analogs of the DNA minor groove binder Hoechst 33258 on topoisomerase II and I mediated activities. Biochim. Biophys. Acta. 1131:1992;53-61.
36. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 65:1996;635-692.